Search - tctmd.com

Displaying 281 - 300 of 324

Sort: Relevancy | Date

Presentation ACVS 2012

Which Antiplatelets to Use for PCI?

Presenter: Dev Pahlajani

August 04, 2012

Presentation ACVS 2012

Peri-Operative Medical Management of Patient with Recurrent Ischemia

Presenter: Ravi Kumar Aluri

August 03, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

L.A. McKeown

August 01, 2012

Presentation

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presenter: Ryota Sakurai

July 12, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

News Daily News

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Caitlin E. Cox

March 07, 2012

News Daily News

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Caitlin E. Cox

March 07, 2012

Advertisement

Which Antiplatelets to Use for PCI?

Peri-Operative Medical Management of Patient with Recurrent Ischemia

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content